Healthcare Value Capital
Latest statistics and disclosures from Healthcare Value Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALKS, PFE, GILD, GlaxoSmithKline, Amryt Pharma Ltd - Spnr, and represent 44.58% of Healthcare Value Capital's stock portfolio.
- Added to shares of these 10 stocks: Proshares Ultrapro Short S&p500, ALKS, Proshares Tr Ii, PFE, VRTX, Proshares Ultrapro Short Qqq, Amryt Pharma Ltd - Spnr, Tyme Technologies, DURECT Corporation, Gamida Cell.
- Started 3 new stock positions in DURECT Corporation, VRTX, Proshares Tr Ii.
- Reduced shares in these 6 stocks: COLL, MDXG, GILD, IRWD, Proshares Tr Ii, Vyne Therapeutics.
- Sold out of its positions in COLL, MDXG.
- Healthcare Value Capital was a net buyer of stock by $2.9M.
- Healthcare Value Capital has $51M in assets under management (AUM), dropping by 0.93%.
- Central Index Key (CIK): 0001458461
Tip: Access up to 7 years of quarterly data
Positions held by Healthcare Value Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Healthcare Value Capital
Healthcare Value Capital holds 23 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alkermes SHS Put Option (ALKS) | 12.2 | $6.2M | +33% | 200k | 30.84 |
|
| Pfizer (PFE) | 10.6 | $5.4M | +25% | 125k | 43.01 |
|
| Gilead Sciences (GILD) | 8.3 | $4.2M | -20% | 60k | 69.85 |
|
| Glaxosmithkline Sponsored Adr | 7.5 | $3.8M | 100k | 38.21 |
|
|
| Amryt Pharma Sponsored Ads | 6.0 | $3.0M | +25% | 250k | 12.09 |
|
| Merck & Co (MRK) | 5.9 | $3.0M | 40k | 75.10 |
|
|
| Astrazeneca Sponsored Adr (AZN) | 5.9 | $3.0M | 50k | 60.06 |
|
|
| Bristol Myers Squibb (BMY) | 5.8 | $3.0M | 50k | 59.18 |
|
|
| Proshares Tr Ultrapro Short S Call Option | 5.2 | $2.6M | +200% | 150k | 17.54 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 5.2 | $2.6M | -20% | 200k | 13.06 |
|
| Clovis Oncology | 4.4 | $2.2M | 500k | 4.46 |
|
|
| Tyme Technologies | 4.1 | $2.1M | +33% | 2.0M | 1.03 |
|
| Antares Pharma | 3.6 | $1.8M | 500k | 3.64 |
|
|
| Proshares Tr Ultrapro Sht Qqq Call Option | 3.4 | $1.7M | +100% | 200k | 8.63 |
|
| Proshares Tr Ii Ultra Vix Short Call Option | 2.4 | $1.2M | NEW | 50k | 24.56 |
|
| Amarin Corp Spons Adr New Call Option | 2.0 | $1.0M | 200k | 5.10 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.8 | $907k | NEW | 5.0k | 181.40 |
|
| Greenlane Hldgs Cl A | 1.6 | $830k | 350k | 2.37 |
|
|
| Vyne Therapeutics | 1.1 | $556k | -11% | 400k | 1.39 |
|
| Adamas Pharmaceuticals | 1.0 | $491k | 100k | 4.91 |
|
|
| Gamida Cell SHS | 0.8 | $392k | +33% | 100k | 3.92 |
|
| DURECT Corporation | 0.6 | $320k | NEW | 250k | 1.28 |
|
| Proshares Tr Ii Vix Sh Trm Futrs Call Option | 0.6 | $285k | -50% | 13k | 22.80 |
|
Past Filings by Healthcare Value Capital
SEC 13F filings are viewable for Healthcare Value Capital going back to 2011
- Healthcare Value Capital 2021 Q3 filed Nov. 15, 2021
- Healthcare Value Capital 2021 Q2 filed Aug. 16, 2021
- Healthcare Value Capital 2021 Q1 filed May 17, 2021
- Healthcare Value Capital 2020 Q4 filed Feb. 16, 2021
- Healthcare Value Capital 2020 Q3 filed Nov. 16, 2020
- Healthcare Value Capital 2020 Q2 filed Aug. 14, 2020
- Healthcare Value Capital 2020 Q1 filed May 15, 2020
- Healthcare Value Capital 2019 Q4 filed Feb. 14, 2020
- Healthcare Value Capital 2019 Q3 filed Nov. 14, 2019
- Healthcare Value Capital 2019 Q2 filed Aug. 14, 2019
- Healthcare Value Capital 2019 Q1 filed May 14, 2019
- Healthcare Value Capital 2018 Q4 filed Feb. 13, 2019
- Healthcare Value Capital 2018 Q3 filed Nov. 14, 2018
- Healthcare Value Capital 2018 Q2 filed Aug. 7, 2018
- Healthcare Value Capital 2018 Q1 filed April 27, 2018
- Healthcare Value Capital 2017 Q4 filed Jan. 23, 2018